Oral Solid
Dosage Forms.
Tablets, powders, capsules and granulation.
Expertise in oral solid dosage forms.
Our approach.
Oral administration remains the most widely used route for the successful delivery of active pharmaceuticals to patients. Upperton is your trusted partner for oral solid dose (OSD) products.
With capabilities covering tablets, powders in bottle/sachet, dry granulation, coated and uncoated tablets and capsules, you can be confident in our expertise in the development and manufacture of oral solid dosage forms.
Guided by a team of experts
Typical OSD development pathway.
Our team offers expert preclinical and clinical formulation development of oral solid dosage (OSD) forms, guiding clients from early feasibility to clinical manufacture. Dosage form design is tailored to factors such as development speed, anticipated dose, excipients to enhance API stability or bioavailability, and targeted or modified release profile requirements.
Preclinical Development
Small scale blends/batches
Clinical Formulation Development
Selection of lead/backup formulations
Scale-up and pilot manufacture to support regulatory submissions
Clinical Manufacture Phase 1-3
Registration/
validation and commercial manufacture
Conventional and SDDs
Tablet formulations.
Whilst capsule delivery represents the faster route into the clinic, tablets give more flexibility in the formulation and offer a more cost-effective solution for products entering later stages of development or commercial manufacture, as well as being a more established approach for targeted delivery.
Conventional
- Particle size/soluble molecules
- Direct blending/dry granulation
- Coating (cosmetic or functional
SDD (Spray Dried Dispersions)
- Poorly soluble molecules
- Dose/API loading
- Disintegration, drug release profile
API, Blend and SDDs
Capsule formulations.
Capsule formulations are often the favoured dosage form for initial clinical studies as they offer a fast, convenient way to deliver the API to the pharmacy.
Capsules may contain simple unformulated API or more advanced formulations, such as amorphous spray-dried dispersions designed to enhance bioavailability.
API
- Dependent on API solubility/BCS class
- Chemical stability required
- API ‘gelling’
Blend
- Common blend or range of blend strengths
- Determine excipient compatibility
SDD (Spray Dried Dispersions)
- Poorly soluble molecules BCS II/IV
- Powder flow/need for compression
- Dispersion/drug release profile
Analytical testing
Phase-appropriate methods are developed for analysis of OSDs from early-stage development, through to GMP manufacture.
- Appearance – visual and microscopic
- Material identification (FTIR)
- Assay and related substances (HPLC, UV, GC)
- Water content (Karl Fischer)
- Residual solvents (GC)
- Blend homogeneity
- Blend density/compressibility
- Content uniformity/weight uniformity
- Tablet hardness/friability
Stability testing
During the preclinical stage, accelerated stability studies focus on excipient compatibility, where API and excipients are blended together and stability assessed with ASAPprime®.
More formal ICH stability studies are used during development to determine product stability/shelf life on technical and clinical batches manufactured under GMP conditions.
